ULUSLARASI MAKALELER

 

 

• Oruc, M. A. Kaplan. Effect of exercise on colorectal cancer prevention and treatment. World J Gastrointest Oncol 2019 May 15; 11(5):348-366. DOI: 10.4251/wjgo.v11.i5.348

• Esin, B. Oksuzoglu, A. Bilici, I. Cicin, O. Kostek, M. A. Kaplan, S. Aksoy, B. Y. Aktas, O. Ozdemir, A. Alacacioglu, D. Cabuk, A. T. Sumbul, A. Sakin, S. Paydas, E. Yetisir, O. Er, T. Korkmaz, N. Yildirim, T. Sakalar, H. Demir, M. Artac, M. Karaagac, H. Harputluoglu, E. Bilen, E. Erdur, S. Degirmencioglu, A. Aliyev, T. Cil, P. Olgun, G. Basaran, O. Gumusay, A. Demir, E. Tanrikulu, P. F. Yumuk, Inanc Imamoglu, B. Oyan, B. Cetin, V. Haksoyler, N. Karadurmus, I. Erturk, T. Evrensel, H. Yilmaz,I. Beypinar, M. Kocer, K. N. Pilanci, M. Seker, Y. Urun, N. Yildirim, T. Eren, U. Demirci. On behalf of Turkish Oncology Group. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Cancer Chemotherapy and Pharmacology;2019:83:131–143.doi:10.1007/s00280-018- 3712-7

• Yersal, M. A. Kaplan, A. Isikdogan, N. Ozdemir, M. Aliustaoglu, S. Barutca, N. Meydan. Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era. MOLECULAR AND CLINICAL ONCOLOGY. 2019;10:180-184. DOI: 10.3892/mco.2018.1771

• Akdeniz, Z. Urakci, M. A. Kaplan, A. Isikdogan. A Rare Tumor in the Colon: A Case of Pleomorphic Sarcoma. World Journal of Surgery and Surgical Research.2018;1:1024:1-3

• Akdeniz, M. A. Kaplan, M. Küçüköner, Z. Urakçı, O. Karhan, A. Işıkdoğan. Pseudocirrhosis in Patients with Metastatic Breast Cancer after Treatment with Eribulin. World Journal of Surgery and Surgical Research. 2018;1:1057:1-3.

• Oruc, M. A. Kaplan, C. Arslan. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients. Expert Opinion on Pharmacotherapy.2018;19;12:1305–1316. doi.org/10.1080/14656566.2018.1504922.

• Kaya, S. Değirmenci, C. Göya, E. T. Tuncel, F. Uçmak, M. A. Kaplan. The importance of acoustic radiation force impulse (ARFI) elastography in the diagnosis and clinical course of acute pancreatitis. Turk J Gastroenterol. 2018 May;29(3):342-347. doi: 10.5152/tjg.2018.17338.

• Kaya, R. Akdogan, F. Uçmak, M. O. Ayyildiz, A. Karakus, M. A. Kaplan. The Incidence and Predictive Factors in the Development of Acute Hepatitis in Patients with Leukemia. Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):31-37. doi: 10.5005/jp- journals-10018-1254.

 

• Cetin, B. Aktas, O. Bal, E. Algin, T. Akman, L. Koral, M. A. Kaplan, U. Demirci, D. Uncu, A. Ozet. Classic Kaposi's sarcoma: A review of 156 cases. Dermatologica Sinica. 2018;36:4:185-9. https://doi.org/10.1016/j.dsi.2018.06.005

• Düzköprü, Z. Oruç, M. A. Kaplan, R. Ülkü, Ç.Tanrıkulu, D. Esmer, A.Bırak, M. Küçüköner, Z. Urakçı, A. Işıkdoğan. The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion. Contemp Oncol (Pozn) 2017; 21 (3): 213–217 DOI: https://doi.org/10.5114/wo.2017.70111

• Oruc, M. A. Kaplan, I.Oruc, Z.Urakci, H.Yerlikaya, M.Kucukoner, A.Isikdogan. Two Malignant Mesothelioma Cases with Brain Metastasis. International Journal of Hematology and Oncology. 2017:2;27:133-136. doi: 10.4999/uhod.171785

• Yildiz, A. Bilici, N. Karadurmuş, L. Kilic, D.Tural, M. A. Kaplan, T. Akman, I.

V. Bayoglu, M. Uysal, Y. Yildiz, Ö.Tanriverdi, O. Yazici, Z. Sürmeli, S. Turhal, S.Bavbek,

F. S. Biricik, D. Koca, M. Basaran. Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy. Tumori 2017;104:6:444-450. DOI: 10.5301/tj.5000635.

• Demirci A, Alkış N, Dane F, Durnalı A, Yazıcı ÖK, Rzayev R, Kaya S, Yazılıtaş D, İnanç M, Özçelik M, Akman T, Kaplan MA, Günaydın Y, Ulaş A, Sönmez Ö, Tokluoğlu S, Gököz Doğu G, Bal Ö, Gümüş M. Retrospective evaluation of premenopausal hormone- sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study. Asia Pac J Clin Oncol. 2017 Apr 21. doi: 10.1111/ajco.12685.

• Oruc, M. A. Kaplan, H. Yerlikaya, M. A.Celik, I. Oruc, Z. Urakci, M.Kucukoner, A.Isikdogan. The Clinical and Demographic Characteristics of Our Cases with Primary Bone Tumors and Soft Tissue Tumors. International Journal of Hematology and Oncology. 2016:3;26:159-166.doi: 10.4999/uhod.161301

• Bozkurt O, Karaca H, Hacıbekiroglu I, Kaplan MA, Duzkopru Y, Uysal M, Berk V, Inanc M, Duran AO, Ozaslan E, Ucar M, Ozkan M. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients? J Chemother. 2016 Jun;28(3):230-4. doi: 10.1179/1973947815Y.0000000039.

• Abakay A, Tanrikulu AC, Ayhan M, Imamoglu MS, Taylan M, Kaplan MA, Abakay

O. High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos. Environ Health Prev Med. 2016 Mar;21(2):82-90. doi: 10.1007/s12199-015-0501-3.

• Kaya M, Baran Ş, Güya C, Kaplan MA. Prevalence and predictive factors for development of splenic artery aneurysms in cirrhosis. Indian J Gastroenterol. 2016 May;35(3):2016. doi: 10.1007/s12664-016-0670-z.

• Sula B, Uçmak F, Kaplan MA, Urakçi Z, Arica M, Isikdogan A. Epidemiological and clinical characteristics of malignant melanoma in Southeast Anatolia in Turkey. Pan Afr Med J. 2016 May 6;24:22. doi: 10.11604/pamj.2016.24.22.9254.

• Kaplan MA, Arslan UY, Işıkdogan A, Dane F, Oksuzoglu B, Inanc M, Akman T, Kucukoner M, Cinkir HY, Rzazade R, Ozkan M, Yilmaz U, Bayoglu IV, Gunaydin Y, Baykara M, Yazilitas D, Cubukcu E, Suner A, Ersoy U, Bilici M, Yazici O, Cayır K, Demirci U, Uysal

M. Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology). Breast Care (Basel). 2016 Aug;11(4):248-252. Epub 2016 Aug 9.

 

• C. Tanrikulu, I. Hocanli, A. Yılmaz, F. Meteroglu, M. Taylan, M. Demir, H. Kaya, A. Abakay, O. Abakay, H. S. Selimoglu, M. A. Kaplan. The Value Of New Inflammatory Parameters In Malignant Mesothelioma Prognosis. Acta Medica Mediterranea, (2015), 31:1: 9-15.

• Tatli AM, Urakci Z, Kalender ME, Arslan H, Tastekin D, Kaplan MA. Alpha- fetoprotein (AFP) elevation gastric adenocarcinoma and importance of AFP change in tumor response evaluation. Asian Pac J Cancer Prev. 2015;16(5):2003-7.

• Bozkurt O, Hacıbekiroglu I, Kaplan MA, Duzkopru Y, Uysal M, Karaca H, Berk V, Inanc M, Duran AO, Ozaslan E, Ucar M, Ozkan M. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients? Clin Genitourin Cancer. 2015 Dec;13(6):548-54. doi: 10.1016/j.clgc.2015.07.005.

• Teke F, Teke M, Inal A, Kaplan MA, Kucukoner M, Aksu R, Urakci Z, Tasdemir B, Isikdogan A. Significance of Hormone Receptor Status in Comparison of 18F -FDG- PET/CT and 99mTc-MDP Bone Scintigraphy for Evaluating Bone Metastases in Patients with Breast Cancer: Single Center Experience. Asian Pac J Cancer Prev. 2015;16(1):387-

• Kucukoner, M. A. Kaplan, A. Inal, Z. Urakci, O. Abakay, A. C.Tanrikulu, A. Abakay, H. S. Selimoglu, G. Turkcu, A. Senyigit, H. Buyukbayram, A. Isikdogan. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey. J BUON. 2014 Jan-Mar;19(1):164-70.

• Inal A, Kaplan MA, Kucukoner M, Urakcı Z, Dostbil Z, Komek H, Onder H, Tasdemir B, Isıkdogan A. Is there any significance of lung cancer histology to compare the diagnostic accuracies of (18)F-FDG-PET/CT and (99m)Tc-MDP BS for the detection of bone metastases in advanced NSCLC? Contemp Oncol (Pozn). 2014;18(2):106-10.

• Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Varol U, Bayoglu IV, Tural D, Kaplan MA, Avci N, Sürmeli Z, Dede İ, Ulaş A, Yazici O, Basaran M. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. Anticancer Res. 2014 Aug;34(8):4329-34.

• Mehmet K, Sener C, Uyeturk U, Seker M, Tastekin D, Tonyali O, Balakan O, Yazici OK, Urakci Z, Isikdogan A, Ozdemir N, Inal A, Kaplan MA, Suner A, Dal S, Uncu D, Gumus M, Boruban MC, Oksuzoglu B, Ayyildiz O, Benekli M. Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology. Contemp Oncol (Pozn). 2014;18(4):273-8.

• Budakoglu B, Altundag K, Aksoy S, Kaplan MA, Ozdemir NY, Berk V, Ozkan M, Algin E, Kandemir N, Dogu GG, Harputluoglu H, Arslan UY, Coskun U, Isikdogan A, Oksuzoglu B. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey. J BUON. 2014 Oct-Dec;19(4):872-8.

• Atay AE, Kaplan MA, Evliyaoglu O, Ekin N, Isıkdogan A. The predictive role of Paraoxonase 1 (PON1) activity on survival in patients with metastatic and nonmetastatic gastric cancer. Clin Ter. 2014;165(1):e1-5. doi: 10.7471/CT.2014.1663.

• Bozkurt O, Karaca H, Ciltas A, Kaplan MA, Benekli M, Sevinc A, Demirci U, Eren T, Kodaz H, Isikdogan A, Ozkan M, Buyukberber S. Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).Asian Pac J Cancer Prev. 2014;15(4):1845-9.

 

• Bozkurt O, Berk V, Kaplan MA, Cetin B, Ozaslan E, Karaca H, Inanc M, Duran AO, Ozkan M. Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.Asian Pac J Cancer Prev. 2014;15(6):2501-4.

• Kaplan MA, Kucukoner M, Inal A, Urakci Z, Evliyaoglu O, Firat U, Kaya M, Isikdogan A.Relationship between Serum Soluble Vascular Adhesion Protein-1 Level and Gastric Cancer Prognosis. Oncol Res Treat. 2014;37(6):340-4. doi: 10.1159/000362626.

• Bestas R, Kaplan MA, Işikdoğan A. The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma. 2014 Mar-Apr;61(130):267-71.

• A. Kaplan, H. Ertugrul, U. Firat, M. Kucukoner, A. Inal, Z. Urakci, Z. Pekkolay, A. Isikdogan. Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab. Breast Cancer, (2014), DOI 10.1007/s12282-013-0513-z.

• Cetin, M. Benekli, I. Turker, L. Koral, A. Ulas, F. Dane, B. Oksuzoglu, M. A. Kaplan, D. Koca, C. Boruban, B. Yilmaz, A. Sevinc, V. Berk, D. Uncu, H. Harputluoglu, U. Coskun, S. Buyukberber. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). Journal of Chemotherapy, (2014), 21:6:300-5. DOI 10.1179/1973947813Y.0000000147.

• Gumusay, U. Coskun, T. Akman, A. S. Ekinci, M. Kocar, O. B. Erceleb, O. Yazıcı, M. A. Kaplan, V. Berk, B. Cetin, B. Y. Taskoylu, A. Yildiz, G. Goksel, A. Alacacioglu, U. Demirci, E. Algin, M. Uysal, I. Oztop, B. Oksuzoglu, F. Dane, M. Gumus,

S. Buyukberber. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. J Cancer Res Clin Oncol, (2014), 140:1:151-7. DOI 10.1007/s00432-013-1553-7.

• A. Kaplan, A. Isikdogan, D. Koca, M. Kucukoner, O. Gumusay, R. Yildiz, A. Dayan, L. Demir, C. Geredeli, M. Kocer, U. Y. Arslan, A. İnal, T. Akman, U. Coskun, N. Sener, M. Inanc, E. T. Elkiran, N. Y. Ozdemir, A. G. Durnalı, A. Suner, S. Alici, M. O. Tarhan, C. Boruban, B. Oksuzoglu, Z. Urakci. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those received trastuzumab-based therapy (A study by Anatolian Society of Medical Oncology). Breast Cancer , (2014), 21:6:677-83. Doi: 10.1007/s12282-013-0441-y

• Berk V, Kaplan MA, Tonyali O, Buyukberber S, Balakan O, Ozkan M, Demirci U, Ozturk T, Bilici A, Tastekin D, Ozdemir N, Unal OU, Oflazoglu U, Turkmen E,Erdogan B, Uyeturk U, Oksuzoglu B, Cinkir HY, Yasar N, Gumus M. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev. 2013;14(12):7367-9.

• Cetin, M. Benekli, F. Dane, C. Boruban, M. Gumus, B. Oksuzoglu, M. A. Kaplan, G. Tufan, A. Sevinc, U. Coskun, S. Buyukberber. Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Breast Care 8:67–70, (2013), DOI: 10.1159/000346829.

• Kefeli, M. Benekli, A. Sevinc, R. Yildiz, M. A. Kaplan, A. Ciltas, O. Balakan, A. Isikdogan, U. Coskun, F. Dane, H. Harputluoglu, H. Karaca, D. Yazilitas, A. Durnali, A. O. Kaya, U. Demirci, M. Gumus, S. Buyukberber. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective

 

multicenter      experience.     Oncol      Letters,     6(2):605-611,      (2013),           DOI: 10.3892/ol.2013.1408.

• Karaca, C. Geredeli, M. A. Kaplan, U. Demirci, S. Alici, M. Artac, A. Isikdogan, M. Benekli, O. Balakan, E. Arpaci, B. Budakoglu, D. Uncu, T. Guler, V. Berk,

M. Ozkan. Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer: A Multicentric Experience. International Journal of Hematology and Oncology, 23; 1-6, (2013), doi: 10.4999/uhod.12009.

• Kaya, D. Isik, R. Bestas, O. Evliyaoglu, V. Akpolat, H. Buyukbayram, M. A. Kaplan. Increased bone mineral density in patients with nonalcoholic steatohepatitis. World Journal of Hepatology, 27; 5(11): 627-634, (2013), doi:10.4254/wjh.v5.i11.627

• Kaya, R. Bestas, M. Cicek, A. Onder, M. A. Kaplan. The value of micro-ELISA test in the diagnosis of Fasciola hepatica infection. Turkiye Parazitol Derg., 37(1):23-7, (2013) doi: 10.5152/tpd.2013.06.

• Baykara, S. Buyukberber, B. Ozturk, U. Coskun, M.A. Kaplan, D.K. Unsal, F. Dane, U. Demirci, H. Bora, M. Benekli; Anatolian Society of Medical Oncology. Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers. Tumori, 99(4):469-73, (2013), doi: 10.1700/1361.15096.

• Demirci, G. Tufan, B. Aktas, O. Balakan, A. Alacacioglu, F. Dane, H. Engin, M.

A. Kaplan, Y. Gunaydin, N. Y. Ozdemir, I. T. Unek, H. Karaca, T. Akman, O. U. Sonmez,

U. Coskun, H. Harputluoglu, A. Sevinc, O. Tonyali, S. Buyukberber, M. Benekli. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Cancer Res Clin Oncol, 139(5):829-35. (2013), DOI 10.1007/s00432-013-1390-8.

• Inal, M. A. Kaplan, M. Kucukoner, Z. Urakci, F. Kilinc, A. Isikdogan. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small- cell lung cancer? Rev Port Pneumol, (2013), 20:2:62-8. doi: 10.1016/j.rppneu.2013.09.001.

• Inal, M. Kucukoner, M. A. Kaplan, Z. Urakci, N. Nas, M. Guven, Z. Dostbil, S. Altindag, A. Isikdogan. Is ¹⁸F-FDG-PET/CT prognostic factor for survival in patientswith small cell lung cancer? Single center experience. Rev Port Pneumol, 19(6):260-5, (2013), doi: 10.1016/j.rppneu.2013.03.007.

• Urun, G. Utkan, A. Kayi Cangir, O. B. Oksuzoglu, N. Ozdemir, D. G. Oztuna,

G. Kocaman, H. .l Coskun, M. A. Kaplan, C. Yuksel, A. Demirkazik, F. Icli. Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey. Asian Pacific Journal of Cancer Prevention, 14 (5), 2801-2803, (2013), DOI:http:// dx.doi.org/10.7314/APJCP.2013.14.5.2801

• Baykara, S. Buyukberber, B. Ozturk, U. Coskun, D. Kılıç Unsal, U. Demirci, F. Dane, M. A. Kaplan, H. Bora, M. Benekli. Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers. Asian Pacific Journal of Cancer Prevention, 14 (4), 2557-2561, (2013), DOI:http://dx.doi.org/10.7314/APJCP.2013.14.4.2557.

• A. Kaplan, A. Inal, M. Kucukoner, Z. Urakci, F. Ekici, U. Firat, S. B. Zincircioglu, A. Isikdogan. Cranial Magnetic Resonance Imaging (MRI) in the Staging of Human Epidermal Growth Factor Receptor (HER) 2-positive Breast Cancer Patients. Onkologie, 36(4):176-81, (2013), doi: 10.1159/000349950.

 

• Abakay, O Abakay, A. C. Tanrıkulu, C. Sezgi, H. Sen, H. Kaya, M. Kucukoner,

M.A. Kaplan, Y. Çelik, A. Senyigit. Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. European Review for Medical and Pharmacological Sciences. 2013;17:19-24.

• A. Kaplan, A. Isikdogan, M. Gumus, U. Y. Arslan, C. Geredeli, N. Ozdemir, D. Koca, F. Dane, A. Suner, E. T. Elkiran, M. Kucukoner, M. Seker, K. Helvaci, T. Guler, D. Uncu, A. Inal, R. Yildiz. Childhood, Adolescents and Young Adults (≤25 Years) Colorectal Cancer (Study of Anatolian Society of Medical Oncology). Journal of Pediatric Hematology/Oncology, 35(2):83-9, (2013), doi: 10.1097/MPH.0b013e31827e7f20.

• Cetin, M. A. Kaplan, V. Berk, G. Tufan, M. Benekli, A. Isıkdogan, M. Ozkan,

U. Coskun, S. Buyukberber. “Bevacizumab-containing Chemotherapy Is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor”, Japanese Journal of Clinical Oncology, 43(1):28-32, (2013), doi:10.1093/jjco/hys175

• Kefeli, S. Buyukberber, M. Akyol, R. Yildiz, M. A. Kaplan, A. Ciltas, A. Sevinc,

H. Karaca, M. Seker, N. Ozdemir, A. Alacacioglu, U. Coskun, A. Isikdogan, F. Dane, M. Gumus, M. Ozkan, A. Suner, M. O. Tarhan, M. Benekli for Anatolian Society of Medical Oncology (ASMO) and Turkish Oncology Group (TOG). “Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumours; retrospective multicenter experience”, Hepato-Gastroenterology, 60(124):647-52, (2013).

• Seker, A. Sevinc, R. Yildiz, S. Cihan, M. A. Kaplan, A. Gokdurnali, F. Dane,

E. Yaman, H. Karaca, D. Colak, U. Uyeturk, A. Bilici, N. Y. Ozdemir, M. E. Kalender, D. Uncu, T. Salepci, A. Isikdogan^., M. Benekli, M. Ozkan, M. Gumus, U. Coskun, C. Camci, B. Oksuzoglu, S. Buyukberber. “Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey.”, Hepato-Gastroenterology, 60(124):768-75, (2013), doi: 10.5754/hge11666.

• Cetin, V. Berk, M. A. Kaplan, B. Afsar, G. Tufan, M. Ozkan, A. Isikdogan, M. Benekli, U. Coskun, S. Buyukberber. “Is the pre-treatment neutrophil to lymphocyte ratio important prognostic parameter in patients with metastatic renal cell carcinoma?”, Clinical Genitourinary Cancer, 11(2):141-8, (2013), DOİ: 10.1016/j.clgc.2012.09.001.

• A. Kaplan, M. Kucukoner, A. Inal, Z. Urakci, U. Firat, H. Komek, A. Isikdogan. Testicular Mass: An Initial Sign of Squamous Cell Carcinoma of the Lung. World J Oncol, 3(6):291-293 (2012), doi: http://dx.doi.org/10.4021/wjon568w.

• Baykara, U. Coskun, V. Berk, M. Ozkan, M. A. Kaplan, M. Benekli, H. Karaca,

M. Inanc, A. Isikdogan, A. Sevinc, E. T. Elkiran, U. Demirci, S. Buyukberber. Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 13 (10), 5119-5124, (2012), DOI:http://dx.doi.org/10.7314/APJCP.2012.13.10.5119

• Yildiz, M. Benekli, M. Ozkan, N. Alkis, V. Berk, M. A. Kaplan, A. Ciltas, H. Karaca, A. G. Durnali, U. Coskun, M. Dikilitas, A. Sevinc, F. Dane, T. Yetisyigit, G. Gokoz Dogu, S. Buyukberber. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. J Cancer Res Clin Oncol, 138:1845–1852, (2012), DOI 10.1007/s00432-012-1264-5.

• Kucukoner, A. Inal, M. A. Kaplan, Z. Urakci, A. Isikdogan. Biased view against biopsy among cancer patients and its reasons. HealthMED. 2012, 6(12):4019-23.

 

• İnal, M. Kucukoner, M. A. Kaplan, Z. Urakci, A. Karakus, H. Komek, Z. Dostbil, A. Isikdogan. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with advanced non-small cell lung cancer: Single center experience. J BUON. 2012 Oct;17(4):724-728.

• Kucukoner, A. Isikdogan, M. Ali Kaplan, A. Inal, S. B. Zincircioglu, M. Cit, T. Cil, Bi. Karadayi, A. Dirier, I. Yildiz. Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer? Wspolczesna Onkol, 16 (5): 416-9, (2012). DOI: 10.5114/wo.2012.31771

• A. Babacan, S. Aksoy, B. Cetin, N.Y. Ozdemir, M. Benekli, U. Uyeturk, M. A. Kaplan, T. Kos, H. Karaca, B. Oksuzoglu, N. Zengin, S. Buyukberber. Multiple primary malignant neoplasms: Multi-center results from Turkey. Journal of BUON. 17: 770-775 (2012)

• Inal, M. A. Kaplan, M. Kucukoner, Z. Urakci, M. Guven, N. Nas, M Yunce, A. Isikdogan. “Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study”, Asian Pac J Cancer Prev, 13 (8), 3869-3872, (2012), Doi: dx.doi.org/10.7314/APJCP.2012.13.8.3869.

• Urun, G. Utkan, S. Yalcin, H. S. Coskun, M. Kocer, N. Y. Ozdemir, M. A. Kaplan, U. Y. Arslan, F. Ozdemir, D. Oztuna, H. Akbulut, F. Icli. “Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group”, Asian Pac J Cancer Prev, 13(8),            4129-4131,                        (2012),

DOI:http://dx.doi.org/10.7314/APJCP.2012.13.8.4129.

• Kucukoner, A. Isikdogan, S. Yaman, O. Gumusay, O. Unal, A. Ulas, E. T. Elkiran, M. A. Kaplan, N. Ozdemir, A. Inal, Z. Urakcı, S. Buyukberber. “Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology”, Asian Pac J Cancer Prev, 13 (8), 3973-3976, (2012), Doi: http://dx.doi.org/10.7314/APJCP.2012.13.8.3973

• Cetin, M. Benekli, B. Oksuzoglu, L. Koral, A. Ulas, F. Dane, I. Turker, M. A. Kaplan, D. Koca, C. Boruban, B. Yilmaz, A. Sevinc, V. Berk, A. Isıkdogan, D. Uncu, H. Harputluoglu, U. Coskun, S. Buyukberber. “Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience.”, Onkologie, 35(12):740-5, (2012), Doi: 10.1159/000345040.

• Kaya, R. Bestas, F. Bacalan, F. Bacaksiz, E. G. Arslan, M. A. Kaplan. “Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients”, World J Gastroenterol, 18, 3585-3589, (2012), DOI: 10.3748/wjg.v18.i27.3585.

• Kaya, R. Bestas, S. Girgin, M. Cicek, M. A. Kaplan. “Increased anti- Echinococcus granulosus antibody positivity in Fasciola hepatica infection”, Turk J Gastroenterol, 23, 339-343, (2012), DOI: 10.4318/tjg.2012.0354.

• Kucukoner, Z. Bilge, A. Isikdogan, M. A. Kaplan, A. Inal, Z. Urakci. “Complementary and Alternative Medicine Usage in Cancer Patients in Southeast of Turkey”, Afr J Tradit Complement Altern Med, (2012), Doi: http://dx.doi.org/10.4314/ajtcam.v10i1.4.

• Kucukoner, E. Arpaci, A. Isikdogan, M. Bilici, D. Uncu, B. Cetin, F. Dane, M. Inanc, A. S. Ekinci, A. Inal, K. Cayir, T. Yetisyigit, N. Ozdemir, M. A. Kaplan, S. Aksoy,

 

N. Alkıs, S. B. Tekin, C. Eroglu, S. Turhal, S. Buyukberber. “Prognostic Analysis of Patients with Operable Gastric Cancer and Tolerability to Adjuvant Radio-Chemo- Therapy”, Neoplasma, 60(1):19-25, (2012), doi: 10.4149/neo_2013_003.

• Altinbas, M. E. Kalender, B. Oven, A. Sevinc, H. Karaca, M. A. Kaplan, S. Alici, E. Arpaci, R. Yildiz, D. Uncu, C. Camci, M. Gumus. “Weekly topotecan for recurrent small cell lung cancer - a retrospective anatolian medical oncology group study”, Asian Pac J Cancer Prev, 13, 2909-2912, (2012), DOI: 10.7314/APJCP.2012.13.6.2909.

• Kucukoner, A. Inal, M. A. Kaplan, Z. Urakci, U. Firat, F. Ucmak, A. Isikdogan, G. Tekbas. “Germ Cell Tumor Located in Gastrointestinal System: A Report of Two Cases”, World J Oncol, 3, 134-137, (2012), doi:10.4021/wjon493w.

• Inal, F. T. Kos, E. Algin, R. Yildiz, V. Berk, I. T. Unek, D. Colak, M. Kucukoner,

E. T. Elkiran, K. Helvaci, C. Geredeli, F. Dane, O. Balakan, M. A. Kaplan, A. G. Durnali,

H. Harputoglu, G. Goksel, N. Ozdemir, S. Buyukberber, M. Gumus, M. Ozkan, M. Benekli,

A. Isikdogan; Anatolian Society Of Medical Oncology. “Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study”, Journal of Balkan Union of Oncology, 17, 102-105, (2012).

• Y. Arslan, B. Oksuzoglu, N. Ozdemir, S. Aksoy, N. Alkis, A. Gok, M. A. Kaplan, M. Gumus, V. Berk, D. Uncu, M. Baykara, D. Colak, U. Uyeturk, I. Turker, A. Isikdogan. “Outcome of non-metastatic male breast cancer: 118 patients”, Med Oncol, 29, 554-560, (2012), DOI: 10.1007/s12032-011-9978-9.

• Inal, M. A. Kaplan, M. Kucukoner, A. Karakus, A. Isikdogan. “Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: A retrospective analysis of single institution”, Journal of Balkan Union of Oncology, 17, 533-536, (2012).

• Ozkan, V. Berk, M. A. Kaplan, M. Benekli, U. Coskun, A. Bilici, M. Gumus, N. Alkis, F. Dane, N. Y. Ozdemir, D. Colak, M. Dikilitas. “Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience”, Neoplasma, 59, 38- 42, (2012), DOI: 10.4149/neo_2012_005.

• Inal, M. A. Kaplan, M. Kucukoner, Z. Urakci, A. Karakus, A. Isikdogan. “Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution”, Asian Pac J Cancer Prev, 13;5; 1837-1840, (2012), Doi: http://dx.doi.org/10.7314/APJCP.2012.13.5.1837.

• Inal, F. T. Kos, E. Algin, R. Yildiz, M. Dikiltas, I. T. Unek, D. Colak, E. T. Elkiran, K. Helvaci, C. Geredeli, F. Dane, O. Balakan, M. A. Kaplan, A. G. Durnali, H. Harputoglu, G. Goksel, N. Ozdemir, S. Buyukberber, M. Gumus, M. Kucukoner, M. Ozkan,

D. Uncu, M. Benekli, A. Isikdogan. “Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study”, Neoplasma, 59, 297-301, (2012), DOI: 10.4149/neo_2012_038.

• Kucukoner, A. Isikdogan, E. Arpaci, M. Bilici, D. Uncu, B. Cetin, F. Dane, M. Inanc, M. A. Kaplan, K. Cayir, T. Yetisyigit, N. Ozdemir, A. Inal, S. Aksoy, N. Alkis, S. B. Tekin, C. Eroglu, S. Turhal, M. Benekli, S. Buyukberber. “Adjuvant Chemoradiation for Gastric Cancer: Multicentric Study of the Anatolian Society of Medical Oncology”, Hepatogastroenterology, 59:119: 2343-7(2012), doi: 10.5754/hge11709

 

• B. Zincircioglu, M. A. Kaplan, A. Isikdogan, T. Cil, B. Karadayi, A. Dirier, M. Kucukoner, A. Inal, I. Yildiz, F. Aggil, O. Donmez, Z. Urakci, Z. Pekkolay, U. Firat. “Contribution of low-molecular weight heparin addition to concomitant hemoradiotherapy in the treatment of glioblastoma multiforme.“, Journal of Balkan Union of Oncology, 17:1: 124-127, (2012).

• A. Kaplan, M. Kucukoner, G. Alpagat, A. Isikdogan. “Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis.” Ann Saudi Med. 32,306-308, (2012), DOI: 10.5144/0256- 4947.2012.306-308

• Cetin, M. A. Kaplan, V. Berk, S. C. Ozturk, M. Benekli, A. Isikdogan, M. Ozkan, U. Coskun, S. Buyukberber. “Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor- targeting agents”, Asian Pac J Cancer Prev, 13, 1059-1063, (2012), Doi: 10.7314/APJCP.2012.13.3.1059

• T. Elkiran, M. A. Kaplan, A. Sevinc, S. Aksoy, U. Demirci, M. Seker, H. Harputluoglu, N. Y. Ozdemir, F. Isik, A. Ulas, M. Inanc, U. Y. Arslan, G. G. Dogu, A. Isikdogan, S. Buyukberber; Anatolian Society of Medical Oncology Group. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Med Oncol, (2012), DOI 10.1007/s12032-012-0276-y

• Inal, M. A. Kaplan, M. Kucukoner, Z. Urakci, A. Karakus, A. Isikdogan. “Prognostic Factors for Second-line Treatment of Advanced Non-small-cell Lung Cancer: Retrospective Analysis at a Single Institution”, Asian Pac J Cancer Prev. 13(4):1281- 1284, (2012). DOI: http://dx.doi.org/10.7314/APJCP.2012.13.4.1277

 

• Inal, M. A. Kaplan, M. Kucukoner, Z. Urakci, A. Karakus, N. Nas, M. Guven,

A. Isikdogan. “Is diabetes mellitus a prognostic factor for survival in patients with small cell lung cancer?”, Asian Pac J Cancer Prev, 13;4; 1491-1494, (2012), DOI: http://dx.doi.org/10.7314/APJCP.2012.13.4.1491

• Inal, M. A. Kaplan, M. Kucukoner, A. Isikdogan. “Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution”, Neoplasma,59, 233-236, (2012), DOI: 10.4149/neo_2012_030

• A. Kaplan, Z. Pekkolay, M. Kucukoner, A. Inal, Z. Urakci, H. Ertugrul, R. Akdogan, U. Firat, I. Yildiz, A. Isikdogan. “Type 2 diabetes mellitus and prognosis in early stage breast cancer women”, Med Oncol, 29,1576-1580, (2012), DOI: 10.1007/s12032- 011-0109-4

• A. Kaplan, A. Isikdogan, D. Koca, M. Kucukoner, O Gumusay, R. Yildiz, A. Dayan, L. Demir, C. Geredeli, M. Kocer, U. Y. Arslan, A. Inal, O. U. Unal, A. G. Mert, M. Bilici, M. Ozkan, E. T. Elkiran, S. Yaman, A. G. Durnalı, A. Suner, S. Alici, M. O. Tarhan,

C. Boruban, Z. Urakci, S. Buyukberber. “Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the anatolian society of medical oncology)”, Oncology, 83,141-150, (2012) Doi: 10.1159/000338782

• Alkis, U. Demirci, M. Benekli, U. Yilmaz, A. Isikdogan, A. Sevinc, N.Y. Ozdemir, D. Koca, T. Yetisyigit, M.A. Kaplan, D. Uncu, T. Unek, M. Gumus. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. Journal of BUON 16: 80-83, (2011).

 

• Kaya, M. A. Kaplan, A. Isikdogan, Y. Celik. “Differentiation of tuberculous peritonitis from peritonitis carcinomatosa without surgical intervention”, Saudi J Gastroenterol, 17, 312-317, (2011), doi: 10.4103/1319-3767.84484.

• Abakay, A. C. Tanrikulu, M. A. Kaplan, M. Kucukoner, O. Abakay, H. Sen, A. Isikdogan, A. Senyigit. “Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma”, Lung India, 28, 267-271, (2011), DOI: 10.4103/0970- 2113.85688.

• Saip, S. Keskin, M. Ozkan, M. A. Kaplan, F. Aydogan, G. G. Demirag, S. Uzunoglu, H. Engin, G. Basaran, N. Guler, K. Uygun, B. Demirkan, F. Ozdemir, E. Cubukcu, T. Salepci, I. Cicin. “The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study”, Journal of Balkan Union of Oncology, 16, 664-671, (2011).

• C. Tanrikulu, A. Abakay, M. A. Kaplan, M. Küçüköner, Y. Palanci, O. Evliyaoglu, C. Sezgi, H. Sen, A. I. Carkanat, G. Kirbas. “A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma”, Respiration, 80, 480-487, (2010), DOI: 10.1159/000321370

• Cil, A. M. Kaplan, A. Altintas, A. M. Akil, S. Alan, A. Isikdogan. “Use of N- terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series”, Clin Drug Investig, 29, 131-137, (2009), doi: 10.2165/0044011-200929020-00007.

• Ozmen, M. A. Kaplan, H. Kaya, D. Akin, R. Danis, B. Kizilkan, O. Yazanel. “Role of lean body mass for estimation of glomerular filtration rate in patients with chronic kidney disease with various body mass indices”, Scand J Urol Nephrol, 43, 171- 176, (2009), DOI: 10.1080/00365590802502228

• Altintas, S. Pasa, T. Cil, M. A. Kaplan, O. Ayyildiz. “Retinoic acid syndrome subsequent to the first dose of all trans retinoic acid”, J Emerg Med, 35, 456-457, (2008), DOI: 10.1016/j.jemermed.2007.11.069

• Cil, M. A. Kaplan, A. Altintas, S. Pasa, A. Isikdogan. “Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: a case report”, Leuk Lymphoma, 48, 1247-1249, (2007), DOI: 10.1080/10428190701332456

• Altintas, T. Cil, I. Kilinc, M. A. Kaplan, O. Ayyildiz. “Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report”, J Neurooncol, 84, 103-105, (2007), DOI: 10.1007/s11060-007-9352-0

• Altintas, O. Ayyildiz, A. Isikdogan, E. Atay, M. A. Kaplan. “Successful initial treatment with caspofungin alone for hepatosplenic candidiasis in a patient with acute myeloblastic leukemia”, Saudi Med J, 27, 1423-1424, (2006).

1.  BİLDİRİLER

 

• ULUSLARARASI BİLDİRİLER

 

• Bilici, S.Menekse, S. Akin, M. Degirmenci, O. F. Olmez, N. Avci, T. Sakalar, D.Tural, M. A. Kaplan, O.Tanriverdi, I. Bilgetekin, R. Uslu. The efficacy and safety analysis of the treatments of everolimus and exemestane combination in 101 metastatic breast cancer patients: Real-life experience from Turkey. 2018 San Antonio Breast Cancer Symposium. P6-18-37.

• Esin, O.B. Cakmak Oksuzoglu, A. Bilici, I. Cicin, S. Aksoy, A. Alacacioglu, M.A. Kaplan, D. Cabuk, A.T. Sumbul, S. Paydas, A. Sakin, O. Er, T. Korkmaz, N. Yildirim, M. Artac, H. Harputluoglu, P.F. Yumuk, G. Basaran, B. Oyan Uluc, U. Demirci. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results. Annals of Oncology, 29 (suppl 8), 104-105, 43th ESMO Congress, Munih, Germany, October 19-23, (2018).

• Akdeniz, M.A. Kaplan, M. Kucukoner, Z. Urakci, O. Karhan, A. Isikdogan. The Role of Serum Carcinoembryonic Antigen to Predict the Response of Treatment in Non- Small Cell Lung Cancer Patients. 19th World Conference on Lung Cancer, Toronto, Kanada, 23-36 Eylül 2018, P3.01-52.
• Akdeniz, M.A. Kaplan, Z. Urakci, M. Kucukoner, O. Karhan, A. Isikdogan. Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer. 19th World Conference on Lung Cancer, Toronto, Kanada, 23-36 Eylül 2018, P2.01-49.
• Akdeniz, M. Küçüköner, M.A.Kaplan, Z.Urakçi, Y. Sezgin, O. Karhan, A. Işikdoğan. ELDERLY PATIENTS WITH COLORECTAL CANCER TREATED OPTIMALLY OR

SUBOPTIMALLY? 2 nd International Congress on Oncological Sciences. S20. 20-23 September 2018 / ANTALYA.

• Karhan, M. Küçüköner, M. A. Kaplan, Z.Urakçi, N. Akdeniz, Y. Sezgin, A. Işikdoğan. BILATERAL BREAST METASTASIS OF RECTUM ADENOCARCINOMA: A RARE

CASE REPORT. 2 nd International Congress on Oncological Sciences. P63. 20-23 September 2018 / ANTALYA.

• A. Kaplan, H. Kavak, Z. Urakci, N. Nas, Z. Oruç, H. Yerlikaya, N. Akdeniz, A. Isikdogan. Is fat mass more effective than body mass index (BMI) to predict toxicity in early breast cancer patients treated with doxorubicin and cyclophosphamide?. 2017 San Antonio Breast Cancer Symposium, San Antonio, Texas, ABD. P6-14-04

• Akdeniz, A. Isikdogan, A. Akbay, Z. Oruc, M.A. Kaplan. Prognostic Value of Body Fat Mass Ratio in Lung Cancer Patients. The IASCL 18^th World Conference on Lung Cancer. Tokyo, Japan. Journal of Thoraic Oncology, November 2017. Volume 12, Issue 11, Supplement 2, Page S2078 (P2.01-024).

• A.Kaplan, Y.Duzkopru, R.Ulku, C.Tanrikulu, M.Kucukoner,S.Onat, A.Abakay, Z. Urakci, F.Meteroglu, Z.Oruc,A.Isikdogan. The importance of serum and fluid Vascular Endothelial Growth Factor (VEGF) level and fluid/serum VEGF ratio in the differential

 

diagnosis of Malign Pleural Mesothelioma (MPM). DOI: 10.1200/JCO.2016.34.15_suppl.e20086 J Clin Oncol, 34 (suppl), abstr e20086, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2016).

• A.Kaplan, Z.Urakci, D.Uncu, F.Dane, M.Ozkan, T.Akman, H.Harputluoglu, B.Ok suzoglu, M.Kucukoner, N.Ozdemir,İ.V.Bayoglu, Y.Gunaydin, M.Baykara, D.Yazilitas, E.Cu bukcu, A.Suner, M.Bilici, A.Isikdogan. Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study. DOI: 10.1200/jco.2015.33.15_suppl.e12052. J Clin Oncol, 33 (suppl), abstr e12052, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, 29 May-2 June, (2015).

• Demirci, N.Alkis, F.Dane, D.Yazilitas, A.Durnali, M.Inanc,M.Ozcelik, T.Akman, O. K.Yazici, M.A.Kaplan, A.Ulas, O.Bal, O.Sonmez, S.Tokluoglu, Y.Gunaydin, G.G.Dogu, O. Tanriverdi, U.Demirci, A.Sevinc, I.Turker. Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue. DOI: 10.1200/jco.2014.32.15_suppl.e11542 J Clin Oncol, 33 (suppl), abstr e11542, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, 29 May-2 June, (2015).

• Isikdogan, Z.Urakci, H.Y.Cinkir, F.Dane, T.Akman,I.V.Bayoglu, Y.Gunaydin, M.B aykara, D.Yazilitas, E.Cubukcu,A.Suner, M.Bilici, U.Ersoy, O.Yazici, M.A.Kaplan. Factors of early recurrence (<24 months) in relapsed node negative early stage breast cancer (the study of Anatolian Society of Medical Oncology).DOI: 10.1200/jco.2015.33.15_suppl.e12066 J Clin Oncol, 33 (suppl), abstr e12066, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, 29 May-2 June, (2015).

• Ozkan, O.Bozkurt, I.Hacibekiroglu, M.A.Kaplan, Y.Duzkopru,M.Uysal, H.Karaca

, V.Berk, M.Inanc, A.O.Duran, E.Ozaslan,M.Ucar. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?. DOI: 10.1200/jco.2015.33.15_suppl.e15624 J Clin Oncol, 33 (suppl), abstr e15624, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, 29 May-2 June, (2015).

• A. Kaplan, H. Odabasi, N. Ozdemir, H. Harputluoglu, M. Aliustaoglu, V. Berk, Y

. Gunaydin, D. Uncu, T. Elkiran, D. Aydin, A Isikdogan. Is lymph node ratio (LNR) having additional contribution for predict prognosis on pathologic lymph node staging in node-positive breast cancer patients? DOI: 10.1158/1538-7445.SABCS15-P3-01-21. Cancer Research, Volume 76, Issue 4 suppl. Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX.

• A. Kaplan, Z. Urakci, M. Gumus, Ü. Yalçintas Arslan, C. Geredeli,N. Ozdemir, D. Koca, Z. Oruc, M. Uysal, F. Dane, A. Sevinc,M. M. Seker, A. Aksoy, M. Kucukoner, K. N. Pilanci, T. Ozturk Topcu, M. Karaagac, R. Yildiz, A. Isikdogan. What are the differences between young (≤25 years) and adults (>25 years) colorectal cancer (CRC)? An Anatolian Society of Medical Oncology Study. DOI: 10.1200/jco.2015.33.15_suppl.e14657. J Clin Oncol, 33 (suppl), abstr e14657, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, 29 May-2 June, (2015).

• Sevinc, M.Seker, R.Yildiz, S.Cihan, M.A.Kaplan, F.Dane,H.Karaca, U.Uyeturk, A

.Bilici, N.Ozdemir, D.Uncu, T.Salepci, A.Isikdogan, M.Benekli, M.Ozkan, M.Gumus, B.Oks uzoglu. The clinical and pathologic characteristics of 400 gastrointestinal stromal tumor patients from Turkey: The final results of the Turkish Anatolian Society of Medical Oncology Multicenter               Registery.    DOI:10.1200/jco.2014.32.15_suppl.e15176.                     J   Clin

 

Oncol, 32 (suppl), abstr e15176, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, 30 May-3 June, (2014).

• Ozkan, O.Bozkurt, H.Karaca, E.Ozaslan, O.O.Daloglu, A.Ciltas, M.A.Kaplan, M. Benekli, A.Sevinc, U.Demirci, T.Eren, H.Kodaz, A.Isikdogan, S.Buyukberber. Efficacy and safety of raltitrexed combinations with uracil-tegafur or Mitomycin C as salvage treatment in advanced colorectal cancer patients. DOI: 10.1200/jco.2014.32.3_suppl.662. J Clin Oncol, 32 (suppl), abstr 662, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, 30 May-3 June, (2014).

• Gumusay, T. Akman, A.S. Ekinci, M. Kocer, O.B. Erceleb, M.A. Kaplan, O. Yazici, V. Berk, B. Cetin, U. Coskun. Predictive factors for the development of brain metastases in patients with malignant melanoma: A study by the Anatolian Society of Medical Oncology. Abstract 3724, 17^th ECMO Congress, 27 September- 1 October 2013,

Amsterdam, Netherland, (2013).

• Cetin, D. Tastekin, B. Aktas, T. Guler, M.A. Kaplan, V. Berk, O. Gumusay, F. Dane, M. Ozkan, M. Benekli. The effects of variability of mean erythrocyte corpuscular volume (MCV) in patients with advanced stage gastrointestinal stromal tumor (GIST) using imatinib on progression free survival. Abstract 2636, 17^th ECMO Congress, 27 September- 1 October 2013, Amsterdam, Netherland, (2013).

• Inal, D. Koca, M.A. Kaplan, M. Kucukoner, Z. Urakci, E. Dogan, A. Isikdogan. Comparison of three different docetaxel and cisplatin plus fluorouracil (DCF) as first-line therapy for advanced gastric cancer: A retrospective analysis of the two institution. Abstract 2605, 17^th ECMO Congress, 27 September- 1 October 2013, Amsterdam,

Netherland, (2013).

• Yildiz, S. Buyukberber, D. Koca, L. Koral, A. Ciltas, O. U. Unal, M. Gumus, N. Ozdemir, F. Dane, V. Berk, M. A. Kaplan, T. Elkiran, M. C. Boruban, U. Coskun, D. Aydin, D. Uncu, M. Ozkan, A. Isikdogan, M. Benekli. The efficacy and safety of first-line and salvage therapies with bevacizumab combination chemotherapy regimens in metastatic colorectal cancer: A retrospective ASMO experience. J Clin Oncol, 31 (suppl), abstr e14705, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2013).

• A. Kaplan, U. Y. Arslan, A. Isikdogan, B. Oksuzoglu, M. Inanc, T. Akman, A. Inal, H. Y. Cankir, M. Kucukoner, B. Budakoglu, M. Ozkan, U. Yilmaz, M. Baykara, D. Yazilitas, U. Ersoy, M. Bilici, E. Cubukcu, O. Yazici, A. Suner, U. Demirci. Biologic subtypes and first relapse pattern in curative surgery performed breast cancer patients: Study of Anatolian Society of Medical Oncology. J Clin Oncol, 31 (suppl), abstr e11559, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2013).

• Urakci, M. A. Kaplan, O. U. Unal, M. Kucukoner, A. Sevinc, I. Oztop, A. Suner, T. Eren, M. Inanc, D. Koca, O. K. Yazici, A. Isikdogan. Efficacy and safety of oral etoposide maintenance therapy following cisplatin plus etoposide in advanced small cell lung cancers (Study of the Anatolian Society of Medical Oncology). J Clin Oncol, 31 (suppl), abstr e18546, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2013).

• Kucukoner, M. A. Kaplan, A. Inal, Z. Urakci, O. Abakay, A. Tanrikulu, A. Abakay, A. Senyigit, A. Isikdogan. Clinical characteristics, treatment, and survival outcomes in malignant pleural mesothelioma: A institution experience in Turkey. J Clin Oncol, 31 (suppl), abstr e18554, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2013).

 

• Kucukoner, E. Arpaci, A. Isikdogan, M. Bilici, D. Uncu, B. Cetin, F. Dane, K. Cayir, M. Inanc, A. S. Ekinci, A. Inal, T. Yetisyigit, N. Ozdemir, M. A. Kaplan, S. Aksoy,

N. Alkis, S. B. Tekin, C. Eroglu, S. Turhal, S. Buyukberber. “Prognostic analysis of the patients with operable gastric cancer and the importance of tolerability of therapy: Study of Anatolian Society of Medical Oncology”, J Clin Oncol, 30 (suppl), abstr e14526, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2012).

• A. Kaplan, A. Isikdogan, D. Koca, M. Kucukoner, O. Gumusay, R. Yildiz, I. Oztop, L. Demir, C. Geredeli, M. Kocer, U. Y. Arslan, A. Inal, U. Coskun, N. Sener, M. Inanc, E. T. Elkiran, N. Ozdemir, A. G. Durnali, A. Suner, S. Alici. “Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study”, J Clin Oncol, 30 (suppl), abstr 638, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2012).

• A. Kaplan, A. Inal, M. Kucukoner, Z. Urakci, F. Ekici, U. Firat, A. Isikdogan. “Cranial magnetic resonance imaging (MRI) in the staging of HER2-positive breast cancer patients”, Oxford University Press, Abstract 387, 37^th ESMO Congress, 28 September- 2 October 2012, Vienna, Austuria, (2012).

• A. Kaplan, Z. Urakci, M. Kucukoner, A. Inal, N. Nas, A. Isikdogan. “Dose delay and reduction profile according to fat mass, body mass index (BMI), and body surface area (BSA) in breast cancer patients treated with doxorubicin and cyclophosphamide (AC) for adjuvant setting”, Abstract Book of International Congress on Nutrition and Cancer, 19, International Congress on Nutrition and Cancer, September 9- 11, Elazig, Turkey, (2012).

• A. Kaplan, M. Kucukoner, A. Inal, Z. Urakci, Z. Pekkolay, A. Isikdogan. “Combination Lapatinib and Capecitabine in Trastuzumab-Rezistant Patients with HER-2⁺ Advanced Breast Cancer”, The Oncologist, International Patients Case Forum Abstracts, 143, Dubai, UAE, October, (2011).

• Cetin, R. Yildiz, B. Oksuzoglu, M. Gumus, U. Yilmaz, A. Ulas, A. Sevinc, A. Isikdogan, U. Y. Arslan, D. Uncu, B. Yilmaz, H. Harputluoglu, D. Koca, A. G. Durnali, S. Buyukberber, I. Turker, M. A. Kaplan, C. Camci, U Coskun, M. Benekli. “Lapatinib Plus Capecitabine for Brain Metastases in Patients with HER-2⁺ Advanced Breast Cancer: Experience of the Anatolian Society of Medical Oncology (ASMO)”, The Oncologist, International Patients Case Forum Abstracts, 56, Dubai, UAE, October, (2011).

• Cetin, R. Yildiz, B. Oksuzoglu, M. Gumus, U. Yilmaz, A. Ulas, A. Sevinc, A. Isikdogan, U. Y. Arslan, D. Uncu, B. Yilmaz, H. Harputluoglu, D. Koca, A. G. Durnali, S. Buyukberber, I. Turker, M. A. Kaplan, C. Camci, U Coskun, M. Benekli. “Lapatinib plus Capecitabine for HER-2⁺ Advanced Breast Cancer: Experience of the Anatolian Society of Medical Oncology (ASMO)”, The Oncologist, International Patients Case Forum Abstracts, 97, Dubai, UAE, October, (2011).

• A. Kaplan, A. Inal, M. Kucukoner, Z. Urakci, A. Isikdogan. “Is Cranial Magnetic Resonance Imaging (MRI) Necessary for Staging of Asymptomatic HER2- Positive Breast Cancer Patients?” Cancer Research 71 (suppl 24) 503, San Antonio Breast Cancer Symposium 2011. San Antonio, Texas, USA, December 6-10, (2011).

• A. Kaplan, A. Isikdogan, M. Gumus, U. Y. Arslan, C. Geredeli, N. Ozdemir, D. Koca, F. Dane, A. Suner, E. T. Elkiran, M. Kucukoner, M. Seker, K. Helvaci, T. Guler, D. Uncu, A. Inal, R. Yildiz. “Childhood, adolescents, and young adults (age 25 and younger) colorectal cancer: A multicenter study”, J Clin Oncol, 29 (suppl), abstr e14127, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2011).

 

• Kucukoner, A. Isikdogan, M. Bilici, S. B. Tekin, D. Uncu, B. Cetin, F. Dane, M. Inanc, M. A. Kaplan, K. Cayir, S. Buyukberber, N. Ozdemir, N. S. Turhal, M. Ozkan, A. Inal, S. Aksoy, M. Benekli. “Adjuvant chemoradiotherapy in 450 patients with gastric cancer: The multicenter retrospective study”, J Clin Oncol, 29 (suppl), abstr e14623, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2011).

• Inal, A. Isikdogan, T. Kos, E. Algin, M. Gumus, M. Dikilitas, E. T. Elkiran, K. Helvaci, C. Geredeli, F. Dane, O. Balakan, A. Gok Durnali, H. Harputluoglu, G. Goksel, N. Ozdemir, S. Buyukberber, R. Yildiz, M. A. Kaplan, M. Ozkan, D. Uncu. “Gemcitabine alone versus gemcitabine plus cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic adenocarcinoma: A retrospective analysis of multicenter study”, J Clin Oncol, 29 (suppl), abstr e14534, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2011).

• A. Babacan, S. Aksoy, B. Cetin, M. A. Kaplan, N. Ozdemir, T. Kos, U. Uyeturk,

H. Karaca, D. Uncu, A. Isikdogan, M. Ozkan, U. Coskun, M. Benekli, S. Buyukberber, N. Zengin. “Clinicopathologic characteristics of multiple primary cancers: 377 patients”, J Clin Oncol, 29 (suppl), abstr e19682, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2011).

• Y. Arslan, O. B. Oksuzoglu, N. Ozdemir, S. Aksoy, N. Alkis, A. Gok Durnali, M.

A. Kaplan, M. Gumus, V. Berk, D. Uncu, M. Baykara, D. Colak, U. Uyeturk, I. Turker, A. Isikdogan. “Outcome of operable male breast carcinoma: One hundred eighteen patients”, J Clin Oncol, 29 (suppl), abstr e11034, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 1-5, (2011).

• Kucukoner, M. A. Kaplan, Z. Bilge, A. Inal, A. Isikdogan. “The use of complementary and alternative therapies in cancer patients of southeastern region of Turkey”, Annals of Oncology, 21 (suppl 8), 371, 35th ESMO Congress, Milan, Italy, October 8-12, (2010).

• B. Zincircioglu, M. A. Kaplan, A. Isikdogan, T. Cil, M. Kucukoner, B. Karadayi,

A. Dirier, I. Yildiz, F. Aggil, O. Donmez. “Contribition of Low-Molecular Weight Heparin addition to Concomitant Chemoradiotherapy in the Treatment of Glioblastome Multiforme”, Annals of Oncology, 21 (suppl 8), 331, 35th ESMO Congress, Milan, Italy, October 8-12, (2010).

• A. Kaplan. “How to Manage Diarrhea and Rash of Lapatinib Plus Capacitabine Combination Therapy”, The Oncologist, International Patients Case Forum Abstracts, 148, Chicago, IL, USA, June 4-8, (2010).

• A. Kaplan, A. Isikdogan, T. Cil. “How to Manage Epistaxis With Lapatinib Plus Capecitabine Combination Therapy” The Oncologist, International Patients Case Forum Abstracts, 148, Chicago, IL, USA, June 4-8, (2010).

• A. Kaplan, A. Işıkdoğan, S. B. Zincircioglu, T. Poyraz, T. Cil, M. Kucukoner,

A. Inal, I. Yildiz, S. Batun, S. Kalkanli. “Vascular endothelial growth factor (VEGF) level in differantial diagnosis of malignant and benign effusion”, J Clin Oncol, 28 (suppl), abstr e21114, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 4-8, (2010).

• Isikdogan, M. A. Kaplan, S. B. Zincircioglu, M. Cit, T. Cil, B. Karadayi, A. Dirier, M. Kucukoner, A. Inal, I. Yildiz. “Concurrent Chemoradiotherapy with or without low molecular weigth heparin (LMWH) in the treatment of locally advanced non-small cell

 

lung cancer (NSCLC)”, J Clin Oncol, 28 (suppl), abstr e17526, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, June 4-8, (2010).

• Cil, A. Altintas, S. Pasa, M. A. Kaplan, S. Alan, A. Isikdogan. “NT-Probnp levels to perspectively assess acut cardiac failure after adjuvant doxorubucine therapy early breast cancer patient”, J Clin Oncol, 26 (suppl), abstr 13541, Annual Meeting of American Society of Clinical Oncology, Chicago, IL, USA, May 30-June 3, (2008).

• Altintas, T. Boyraz, S. Pasa, T. Cil, M. A. Kaplan, O. Ayyildiz. “Pulmonary Hypertension in Essential Thrombocythemia” Hematologica / The Hematology Journal, 92 (suppl), 239, 12th Congress of the Europan Hematology Association, Vienna, Austria, June 7-10, (2007).

• Cil, A. Altintas, S. Pasa, M. Kaplan, A. Isikdogan. “Hepatitis B and C viruses seroprevalence of cancer patients in southeastern region of Turkey”, EJC Abstract Book, 5(4), 170, ECCO 14, 23-27 September, Barcelona, (2007).

• Cil, A. Isikdogan, A. Altintas, S. Sayar, M. A. Kaplan, H. Buyukbayram. “Prognostic Factors Affecting Local Reccurence and Systemic Metastasis for Patients With Early Breast Cancer”, Annals of Oncology, 17 (suppl 9), 113, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3, (2006).

• Cil, A. Altintas, M. A. Kaplan, O. Ayyildiz. “Clinical Characteristics of Gastrointestinal Stromal Tumors in Southeast Region of Turkey”, Annals of Oncology, 17 (suppl 9), 167, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3, (2006).

• Altintas, A. Isikdogan, O. Ayyildiz, M. A. Kaplan, T. Cil, A. E. Atay, H. Buyukbayram, E. Muftuoglu. “Hodgkin’s Disease in Southeast Region of Turkey: Clinicopathologic Features of 138 Cases”, Annals of Oncology, 17 (suppl 9), 207, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3, (2006).

• Altintas, T. Cil, O. Ayyildiz, A. E. Atay, M. A. Kaplan, A. Isikdogan, E. Muftuoglu. “Clinical Outcome of Patients With Hairy Cell Leukemia”, Annals of Oncology,

17 (suppl 9), 209, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3,

(2006).

• Altintas, T. Cil, M. A. Kaplan, A. E. Atay, A. Isikdogan, O. Ayyildiz, E. Muftuoglu. “Hepatitis C Virus in Patients With Non-Hodgkin’s Lymphoma in Southeastern of Turkey”, Annals of Oncology, 17 (suppl 9), 210, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3, (2006).

• A. Kaplan, T. Cil, A. Altintas, A. Isikdogan, O. Ayyildiz, E. Muftuoglu. “Relation of HBV İnfection and Lymphoma in Southeast of Turkey”, Annals of Oncology,

17 (suppl 9), 210, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3,

(2006).

• Altintas, M. A. Kaplan, T. Cil, A. E. Atay, A. Isikdogan, O. Ayyildiz, E. Muftuoglu. “Disturbance of Hematologic Malignencies Between 1995-2005: A Single Center Experience from Southeastern Region of Turkey”, Annals of Oncology, 17 (suppl 9), 210, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3, (2006).

• Altintas, T. Cil, O. Ayyildiz, M. A. Kaplan, A. E. Atay, A. Isikdogan, E. Muftuoglu. “Thalidomide-Associated Trombosis in Multiple Myeloma”, Annals of Oncology,

17 (suppl 9), 211, 31th ESMO Congress, Istanbul, Turkey, September 29-October 3,

(2006).

 

• Altintas, T. Cil, O. Ayyildiz, M. A. Kaplan, A. Isikdogan, E. Muftuoglu, A. E. Atay. “Results of Imatinib Mesylate Therapy in Chronic Myeloid Leukemia”, Annals of Oncology, 17 (suppl 9), 211, 31th ESMO Congress, Istanbul, Turkey, September 29-

October 3, (2006).

• Altintas, O. Ayyildiz, A. Isikdogan, A. E. Atay, M. A. Kaplan. “Successful İnitial Treatment with Caspofungin alone for Hepatosplenic Candisiasis in Patient with Acute Myeloblastic Leukemia”, Abstract Book of The First İnternational Congress of Central Asia İnfectious Diseases, 113, The First İnternational Congress of Central Asia İnfectious Diseases Bishkek, Kyrgyzstan, October 30-November 2, (2006).